CASI Pharmaceuticals, Inc.
CASI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 0.03 | -0.01 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -4.22 | -2.76 | -3.89 | -5.38 |
| Quality | ||||
| ROIC | -274.05% | -108.90% | -40.54% | -35.25% |
| Gross Margin | 22.96% | 49.29% | 58.00% | 24.17% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -14.04% | -10.24% | -9.55% | -12.85% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.47 | -1.09 | -0.72 | -0.89 |
| Interest Coverage | -54.75 | -45.59 | -52.69 | -18.61 |
| Efficiency | ||||
| Inventory Turnover | 0.91 | 0.62 | 0.63 | 1.93 |
| Cash Conversion Cycle | 154.28 | 225.80 | 211.19 | 125.88 |